Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial
Watch Merck &'s latest callMerck & (NYSE:MRK) Q2 2026 Earnings Call · Replay · Aug 4Read the transcript of Merck & (NYSE:MRK) Q2 2026 Earnings CallThe original release is unavailable here.
In the deck
Story so far
- Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
- European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)
- U.S. FDA Approves Updated Indication for WINREVAIR™ (sotatercept-csrk) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) Based on Phase 3 ZENITH Study
Earlier from Merck &
- Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
- Codexis Reports Third Quarter 2025 Financial Results
- Alliance for Building Better Medicine and the Virginia Innovation Partnership Celebrate $120 Million Investment from AstraZeneca, Eli Lilly, and Merck to Advance Virginia's Advanced Pharmaceutical Manufacturing Workforce
- Quebec Expands Public Funding for CAPVAXIVE®
- Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)
Later from Merck &
- Merck to Participate in the Jefferies Global Healthcare Conference in London
- Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent
- Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)
- Merck Announces First-Quarter 2026 Dividend
- European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union
Follow Merck & into a list and get an email when it puts out news.
Follow Merck &